/RNA
RNA Stock - Avidity Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$72.43+0.11%
+$0.08 (+0.11%) • Jan 13
64
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.83
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).49
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.82
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-0.6%upside
Target: $72.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RNA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$71.71 – $73.15
TARGET (TP)$72.00
STOP LOSS$66.64
RISK/REWARD1:-0.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.96
52W High$72.61
52W Low$21.51
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.90M | $9.56M | $9.22M | $9.33M | $6.79M |
| Gross Profit | $10.90M | $7.46M | $7.84M | $-91,856,000 | $-30,815,000 |
| Gross Margin | 100.0% | 78.0% | 85.0% | -984.9% | -454.0% |
| Operating Income | $-378,936,000 | $-235,598,000 | $-178,913,000 | $-118,051,000 | $-44,277,000 |
| Net Income | $-322,302,000 | $-212,220,000 | $-173,995,000 | $-118,009,000 | $-44,355,000 |
| Net Margin | -2957.7% | -2219.9% | -1886.3% | -1265.4% | -653.5% |
| EPS | $-2.89 | $-2.91 | $-3.34 | $-2.85 | $-2.05 |
Company Overview
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
RNABeat Rate
50%
Last 18 quarters
Avg Surprise
-1.5%
EPS vs Estimate
Beats / Misses
9/9
Last 12 quarters
Latest EPS
$-1.27
Q4 2025
EPS Surprise History
Q1 24
-46.3%
$-0.79vs$-0.54
Q2 24
+2.5%
$-0.79vs$-0.81
Q3 24
+14.5%
$-0.65vs$-0.76
Q4 24
+8.5%
$-0.65vs$-0.71
Q1 25
-5.3%
$-0.80vs$-0.76
Q2 25
-2.3%
$-0.90vs$-0.88
Q3 25
-27.4%
$-1.21vs$-0.95
Q4 25
-16.5%
$-1.27vs$-1.09
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-1.11 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-1.09 | $-1.27 | -16.5% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.95 | $-1.21 | -27.4% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.88 | $-0.90 | -2.3% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.76 | $-0.80 | -5.3% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.71 | $-0.65 | +8.5% | ✓ BEAT |
Q3 2024 | Aug 9, 2024 | $-0.76 | $-0.65 | +14.5% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.81 | $-0.79 | +2.5% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.54 | $-0.79 | -46.3% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.76 | $-0.71 | +6.6% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.84 | $-0.66 | +21.4% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.90 | $-0.74 | +17.8% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.84 | $-0.88 | -4.8% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.97 | $-0.82 | +15.5% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.74 | $-0.92 | -24.3% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.94 | $-0.71 | +24.5% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-0.73 | $-0.82 | -12.3% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.63 | $-0.68 | -7.9% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-0.77 | $-0.70 | +9.1% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about RNA
What is RNA's current stock price?
Avidity Biosciences, Inc. (RNA) is currently trading at $72.43 per share. The stock has moved +0.11% today.
What is the analyst price target for RNA?
The average analyst price target for RNA is $72.00, based on 1 analyst.
What sector is Avidity Biosciences, Inc. in?
Avidity Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is RNA's market cap?
Avidity Biosciences, Inc. has a market capitalization of $9.51 billion, making it a mid-cap company.
Does RNA pay dividends?
No, Avidity Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABVX
Abivax S.A.
$119.64
Mkt Cap: $7.8B
CAI
Caris Life Sciences, Inc.
$26.40
Mkt Cap: $7.4B
CYTK
Cytokinetics, Incorporated
$63.33
Mkt Cap: $7.5B
JAZZ
Jazz Pharmaceuticals plc
$162.43
Mkt Cap: $9.9B
MDGL
Madrigal Pharmaceuticals, Inc.
$493.90
Mkt Cap: $11.0B
MRNA
Moderna, Inc.
$39.60
Mkt Cap: $15.5B
MRUS
Merus N.V.
$90.00
Mkt Cap: $6.8B
NUVL
Nuvalent, Inc.
$101.17
Mkt Cap: $7.4B
RYTM
Rhythm Pharmaceuticals, Inc.
$107.80
Mkt Cap: $7.2B
TECH
Bio-Techne Corporation
$66.36
Mkt Cap: $10.4B
Explore stocks similar to RNA for comparison